Objectives: Mesenchymal stem cells (MSC) derived from adipocytes would decrease inflammatory reaction and have im-munomodulatory effect.In this study we have used a mouse model of allergen induced airway inflammation to determine wheth-er administering MSC would reduce levels of eosinophilic inflammation in asthma. Methods: Male, BALB/c mice (asthma group n=8, asthma+MSC group n=8) were used. Sensitization of BALB/c mice was performed by intraperitoneal injection OVA on day 0, 7, 14, 21 and sensitized BALB/c mice were challenged with OVA intra-nasally on day 28, 30, 32. Mice were administered either a MSC (6×100,000 cells) or a PBS via intraperitoneal injection on day 27. Tissue specimens and bronchoalveolar lavage fluid (BALF) were obtained for immunohistochemical analysis (H&E, MBP (anti-major basic protein)and PAS (periodic acid-Schiff)), and ELISA (enzyme-linked immunosorbent assay). Results: Mice administered the MSC had significantly reduced level of eosinophilic inflammation compared to asthma group (2.54 vs 4.72 eosinophils/bronchiole,p=0.00) as well as reduced levels of PAS+mucine cells (2.55% vs 10.54% mucin cells/epi-thelial cell %, p=0.04). Mice administered the MSC had also reduced level of eotaxin-1 (0.040 vs 0.045 pg/ml, p=0.83), IL-4(0.085 vs 0.090 pg/ml, p=0.60), and IL-13(0.069 vs 0.108 pg/ml, p=0.17) but not significant. Conclusions: The result revealed that immunomodulatory properties of mesenchymal stem cells might have effect on airway inflammation of asthma.